Stock listing
Lang & Schwarz:900006 Artivion, Inc. Aktie
German listing (Lang & Schwarz) of Artivion, Inc. · home listing NYSE:AORT
Follow Artivion, Inc. into a list and get an email when it puts out news.
Home listing price · NYSE:AORT
$18.16 USD -0.38 (-2.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:AORT
- Day range
- $18.13 – $18.93 USDNov 20, 2026
- Volume
- 642,096 sharesNov 20, 2026
- Market cap
- $886.0M USDAt the close on Nov 20, 2026 · price × 48.79M shares outstanding
- 52-week range
- $18.12 – $48.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15.47M USDMedian day 561,739 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:AORT · Home | $18.16 USD | -0.38 (-2.0%) | 642,096 | $18.52 | $18.93 | $18.13 | $18.54 | Close on Nov 20, 2026 |
| Frankfurt:CYL | €16.70 EUR | -0.30 (-1.8%) | — | €16.70 | €16.70 | €16.70 | €17.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:AORT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $18.16 | -0.38 | -2.0% | $18.52 | $18.93 | $18.13 | 642,096 | |
| $18.54 | +0.27 | +1.5% | $18.17 | $18.77 | $18.17 | 913,922 | |
| $18.27 | -0.20 | -1.1% | $18.19 | $18.68 | $18.13 | 561,739 | |
| $18.47 | -0.63 | -3.3% | $19.27 | $19.33 | $18.12 | 523,784 | |
| $19.10 | -0.30 | -1.5% | $19.62 | $19.81 | $18.95 | 557,998 | |
| $19.40 | -0.70 | -3.5% | $20.06 | $20.77 | $19.20 | 855,181 | |
| $20.10 | -0.37 | -1.8% | $20.25 | $20.73 | $20.05 | 646,227 | |
| $20.47 | -0.17 | -0.8% | $20.43 | $20.68 | $19.21 | 997,934 | |
| $20.64 | +0.43 | +2.1% | $20.32 | $21.06 | $19.33 | 1,662,766 | |
| $20.21 | -5.12 | -20.2% | $22.19 | $23.01 | $19.74 | 3,247,000 | |
| $25.33 | -1.12 | -4.2% | $26.93 | $27.00 | $24.69 | 1,127,700 | |
| $26.45 | +2.74 | +11.6% | $24.45 | $26.69 | $24.45 | 1,086,400 | |
| $23.71 | +0.13 | +0.6% | $23.56 | $23.94 | $23.22 | 645,700 | |
| $23.58 | +1.00 | +4.4% | $22.87 | $23.93 | $22.82 | 626,200 | |
| $22.58 | -0.86 | -3.7% | $23.62 | $23.62 | $21.85 | 627,400 | |
| $23.44 | +0.52 | +2.3% | $23.80 | $23.80 | $23.05 | 418,200 | |
| $22.92 | -0.02 | -0.1% | $22.59 | $23.38 | $22.59 | 421,600 | |
| $22.94 | -0.04 | -0.2% | $22.98 | $23.15 | $22.61 | 405,200 | |
| $22.98 | -0.32 | -1.4% | $23.12 | $23.63 | $22.91 | 366,000 | |
| $23.30 | -0.67 | -2.8% | $23.86 | $24.20 | $22.91 | 415,300 | |
| $23.97 | +1.07 | +4.7% | $23.03 | $24.24 | $23.03 | 544,400 | |
| $22.90 | -0.19 | -0.8% | $22.76 | $23.31 | $22.69 | 473,800 | |
| $23.09 | +0.81 | +3.6% | $22.95 | $23.69 | $22.81 | 631,100 | |
| $22.28 | +0.50 | +2.3% | $21.68 | $22.51 | $21.52 | 465,100 | |
| $21.78 | -0.09 | -0.4% | $21.83 | $22.37 | $21.64 | 433,600 | |
| $21.87 | +0.34 | +1.6% | $22.02 | $22.49 | $21.53 | 512,500 | |
| $21.53 | +0.17 | +0.8% | $21.32 | $21.75 | $21.08 | 488,500 | |
| $21.36 | -0.43 | -2.0% | $21.83 | $22.40 | $21.30 | 664,600 | |
| $21.79 | +0.53 | +2.5% | $21.21 | $21.91 | $21.09 | 436,600 | |
| $21.26 | +0.05 | +0.2% | $21.15 | $21.60 | $20.21 | 343,500 | |
| $21.21 | -0.40 | -1.9% | $21.45 | $21.45 | $20.89 | 602,200 | |
| $21.61 | -0.23 | -1.1% | $21.80 | $22.40 | $21.59 | 352,000 | |
| $21.84 | -0.77 | -3.4% | $22.83 | $23.31 | $21.65 | 494,300 | |
| $22.61 | +0.30 | +1.3% | $22.21 | $23.04 | $22.16 | 734,200 | |
| $22.31 | +0.38 | +1.7% | $22.07 | $22.72 | $21.60 | 559,400 | |
| $21.93 | -0.89 | -3.9% | $22.87 | $23.11 | $21.86 | 501,700 | |
| $22.82 | -0.04 | -0.2% | $22.91 | $23.11 | $22.64 | 501,400 | |
| $22.86 | -0.09 | -0.4% | $22.90 | $23.07 | $22.41 | 336,500 | |
| $22.95 | +0.32 | +1.4% | $22.63 | $23.21 | $22.42 | 446,100 | |
| $22.63 | -0.40 | -1.7% | $23.06 | $23.30 | $22.52 | 502,800 | |
| $23.03 | -0.50 | -2.1% | $23.59 | $23.72 | $23.00 | 567,200 | |
| $23.53 | -0.60 | -2.5% | $24.15 | $24.76 | $23.03 | 504,000 | |
| $24.13 | +0.50 | +2.1% | $23.93 | $24.15 | $23.44 | 605,400 | |
| $23.63 | +0.28 | +1.2% | $23.27 | $23.72 | $22.92 | 569,100 | |
| $23.35 | -0.53 | -2.2% | $23.80 | $24.26 | $23.30 | 1,914,800 | |
| $23.88 | -1.14 | -4.6% | $24.96 | $25.14 | $23.71 | 572,600 | |
| $25.02 | -0.36 | -1.4% | $25.33 | $25.48 | $24.96 | 683,200 | |
| $25.38 | +0.41 | +1.6% | $24.89 | $25.75 | $24.40 | 949,000 | |
| $24.97 | -0.11 | -0.4% | $25.61 | $25.74 | $24.83 | 599,000 | |
| $25.08 | +0.43 | +1.7% | $24.96 | $25.28 | $24.40 | 547,900 | |
| $24.65 | -0.57 | -2.3% | $25.12 | $25.40 | $24.50 | 694,500 | |
| $25.22 | +0.09 | +0.4% | $25.15 | $25.72 | $24.72 | 553,800 | |
| $25.13 | -0.44 | -1.7% | $25.42 | $25.81 | $24.92 | 619,400 | |
| $25.57 | -0.05 | -0.2% | $25.37 | $25.69 | $25.18 | 418,300 | |
| $25.62 | -0.72 | -2.7% | $26.50 | $26.90 | $25.45 | 438,800 | |
| $26.34 | -0.75 | -2.8% | $26.93 | $27.92 | $26.29 | 549,500 | |
| $27.09 | +0.10 | +0.4% | $27.05 | $27.95 | $26.92 | 675,100 | |
| $26.99 | +0.22 | +0.8% | $26.46 | $27.10 | $25.86 | 669,100 | |
| $26.77 | +0.10 | +0.4% | $26.71 | $27.11 | $26.69 | 466,500 | |
| $26.67 | -0.53 | -1.9% | $26.92 | $27.34 | $26.58 | 440,800 | |
| $27.20 | +0.82 | +3.1% | $26.18 | $27.42 | $26.02 | 609,000 | |
| $26.38 | -0.51 | -1.9% | $26.89 | $27.15 | $26.19 | 735,700 | |
| $26.89 | -1.19 | -4.2% | $28.01 | $28.17 | $26.77 | 1,036,000 | |
| $28.08 | +0.10 | +0.4% | $27.86 | $28.61 | $27.82 | 484,900 | |
| $27.98 | -0.84 | -2.9% | $28.49 | $29.01 | $27.77 | 819,300 |
Splits
2 splits since 1996 · NYSE:AORT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-2 | Split | |
| 2-for-1 | Split |
- Ticker
- Lang & Schwarz:900006
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Artivion Reports Third Quarter 2026 Financial Results
Latest earnings call · Nov 5, 2026
Artivion (NYSE:AORT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 6, 2026
Q2 2026 Earnings Presentation
Earnings · 22 slides
Latest news
Artivion Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $20.21 (-20.2%) on Nov 6, 2026
Artivion to Participate in Upcoming Investor Conferences
Oct 28, 2026
Closed $23.44 (+2.3%) on Oct 29, 2026
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
Oct 22, 2026
Closed $23.30 (-2.8%) on Oct 23, 2026
Artivion Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $27.12 (+2.1%) on Aug 7, 2026
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Jul 23, 2026
Closed $25.28 (+1.1%) on Jul 24, 2026
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Jun 29, 2026
Closed $22.39 (-5.2%) on Jun 29, 2026
Artivion to Participate in the 2026 Truist Securities MedTech Conference
Jun 10, 2026
Closed $20.60 (+0.6%) on Jun 11, 2026
Artivion Completes Acquisition of Endospan Ltd.
May 18, 2026
Closed $23.76 (+4.3%) on May 18, 2026
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
May 7, 2026
Closed $25.41 (-28.3%) on May 8, 2026
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Apr 23, 2026
Closed $37.76 (+1.6%) on Apr 24, 2026
Artivion, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 15 in the last 12 months · 31 in all · newest Nov 5, 2026 · oldest 2025
- Calls
- 32 calls with a replay · 32 with a transcript · latest Nov 5, 2026
- Decks
- 14 decks · latest Aug 6, 2026
Where Artivion, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:AORT · Home listing | NYSE | United States | USD |
| gettex:CYL | gettex | Germany | EUR |
| LS Exchange:900006 | LS Exchange | Germany | EUR |
| Lang & Schwarz:900006 · This page | Lang & Schwarz | Germany | EUR |
| BOATS:AORT | BOATS | United States | USD |
| Frankfurt:CYL | Frankfurt | Germany | EUR |
| Hamburg:CYL | Hamburg | Germany | EUR |
| Dusseldorf:CYL | Dusseldorf | Germany | EUR |
| Stuttgart:CYL | Stuttgart | Germany | EUR |
| Tradegate:CYL | Tradegate | Germany | EUR |
Valuation
EV/sales 2.5× against a median of 2.8×: 6th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.20B USD
- P/E
- Loss
- EV/sales
- 2.5×
- EV/EBITDA
- 32.3×
- Price/book
- 2.0×
- Gross margin
- 63.3%
- Operating margin
- 2.3%
- Net margin
- −3.6%
- Debt to equity
- 0.8×
- Beta vs S&P 500
- 0.42
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Artivion, Inc. · NYSE:AORT | US$886.0M | US$1.20B | n/a | 2.5× | 32.3× | 2.0× | −3.6% | 0.8× | 0.42 |
| Shenzhen Edge Medical Co., Ltd. Class H · HKEX:2675 | US$973.0M | US$695.3M | n/a | 10.2× | n/a | 2.8× | −19.4% | 0.0× | n/a |
| Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. Class A · SZSE:301234 | US$952.4M | US$890.2M | 354× | 14.4× | n/a | 8.3× | 4.3% | 0.0× | n/a |
| Edan Instruments, Inc. Class A · SZSE:300206 | US$939.7M | US$748.4M | 16.9× | 2.3× | n/a | 2.7× | 17.1% | 0.0× | n/a |
| Arjo AB Class B · OMXSTO:ARJO_B | US$904.9M | US$1.35B | 25.6× | 1.2× | 6.8× | 1.1× | 3.3% | 0.7× | n/a |
| Kuros Biosciences Ltd. · SIX:KURN | US$889.2M | US$892.9M | 352× | 6.2× | 74.9× | 10.4× | 1.8% | 0.1× | n/a |
| Hartalega Holdings Bhd. · MYX:HARTA | US$870.5M | US$585.7M | 20.4× | 1.1× | 6.0× | 0.8× | 7.6% | 0.0× | n/a |
| OrthoPediatrics Corp. · NASDAQ:KIDS | US$828.7M | US$889.1M | n/a | 3.4× | n/a | 2.4× | −12.8% | 0.3× | 0.78 |
| Modern Dental Group Limited · HKEX:3600 | US$819.4M | US$791.3M | 10.8× | 1.7× | 7.1× | 1.8× | 16.0% | 0.2× | n/a |
| Aidite (Qinhuangdao) Technology Co., Ltd. Class A · SZSE:301580 | US$818.5M | US$614.5M | 27.1× | 3.5× | n/a | 2.4× | 17.4% | 0.0× | n/a |
| Zhonghong Pulin Medical Products Co., Ltd. Class A · SZSE:300981 | US$818.2M | US$309.6M | 36.8× | 0.8× | n/a | 1.0× | 5.4% | 0.0× | n/a |
| Median of the others | US$879.8M | US$769.8M | 26.3× | 2.8× | 7.0× | 2.4× | 4.9% | 0.0× | 0.78 |
Forecasts
7 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 38.47 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.37 · 6 analysts
- Revenue, year to Dec 2026
- 489.3M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| J. Patrick Mackin | Chairman, President and Chief Executive Officer |
| Marna P. Borgstrom | Chief Executive Officer |
| Lance Berry | Executive Vice President, Chief Operating Officer, and Chief Financial Officer |
| Thomas F. Ackerman | Executive Vice President and Chief Financial Officer |
| Jean F. Holloway | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| Amy D. Horton | Vice President, Chief Accounting Officer |
| Andrew M. Green | Senior Vice President, Regulatory and Quality |
| Brian Johnston | Executive Vice President |
| Carlos Soto | Vice President, Global Manufacturing |
| Jason Asper | Senior Vice President and Chief Strategy and Digital Officer |
| Matthew A. Getz | Vice President, Chief Human Resources Officer |
| Robert C. Thomson | Vice President, Research and Development |
| Rochelle L. Maney | Vice President, Global Quality |
| Simona Zannetti | Senior Vice President of Clinical Research and Chief Medical Officer |
| Elizabeth A. Hoff | Consultant and Founder |
| John E. Davis | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| J. Patrick Mackin | Chairman, President and Chief Executive Officer |
| Jon W. Salveson | Vice Chairman, Investment Banking |
| Anthony Semedo | Director |
| Daniel J. Bevevino | Director |
| Elizabeth A. Hoff | Consultant and Founder |
| Jeff Burbank | Lead Director |
| Marna P. Borgstrom | Chief Executive Officer |
| Thomas F. Ackerman | Executive Vice President and Chief Financial Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Artivion (NYSE:AORT) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q1 2025 Earnings Call | Mon, May 05, 2025 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q4 2024 Earnings Call | Mon, Feb 24, 2025 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| Artivion (NYSE:AORT) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −20.2% |
| Q2 2026 | Aug 6, 2026 · After close | +2.1% |
| Q1 2026 | May 7, 2026 · After close | −28.3% |
| Q4 2025 | Feb 12, 2026 · After close | −10.0% |
| Q3 2025 | Nov 6, 2025 · After close | −5.5% |
| Q2 2025 | Aug 7, 2025 · After close | +25.2% |
| Q1 2025 | May 5, 2025 · After close | +15.4% |
| Q4 2024 | Feb 13, 2025 · Before open | +1.0% |
| Q3 2024 | Nov 7, 2024 · After close | −0.9% |
| Q2 2024 | Aug 8, 2024 · After close | −1.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | +12.8% |
| Q4 2023 | Feb 15, 2024 · After close | +4.3% |
| Q3 2023 | Nov 2, 2023 · After close | +9.9% |
| Q2 2023 | Aug 3, 2023 · After close | −1.6% |
| Q1 2023 | May 4, 2023 · After close | +13.8% |
| Q4 2022 | Feb 16, 2023 · After close | +5.8% |
| Q3 2022 | Nov 3, 2022 · After close | −1.9% |
| Q2 2022 | Aug 4, 2022 · After close | −2.6% |
| Q1 2022 | May 5, 2022 · After close | −4.3% |
| Q4 2021 | Feb 17, 2022 · After close | +1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 22 slides | Aug 6, 2026 |
| Investor Presentation (August 2026) | Investor deck | 23 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 20 slides | May 7, 2026 |
| Investor Presentation (May 2026) | Investor deck | 20 slides | May 2026 |
| Q4 2025 Earnings Presentation | Earnings | 22 slides | Feb 12, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 19 slides | Aug 7, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 20 slides | May 5, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 16 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 16 slides | Aug 8, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 17 slides | May 6, 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2020) | Investor deck | 28 slides | Dec 7, 2020 |
| Cryolife — Investor Presentation (February 2016) | Investor deck | 44 slides | Feb 16, 2016 |
| Cryolife — Investor Presentation (November 2011) | Investor deck | 25 slides | Nov 15, 2011 |
| CryoLife — Merger or Acquisition (March 2011) | Merger or acquisition | 8 slides | Mar 29, 2011 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 441.3M | 388.5M | 354.0M | 313.8M | 298.8M | 253.2M | 276.2M | 262.8M | 189.7M | 180.4M |
| Cost of revenue | 157.1M | 139.8M | 124.8M | 111.3M | 101.3M | 85.4M | 93.2M | 89.9M | 61.1M | 61.5M |
| Gross profit | 284.2M | 248.8M | 229.2M | 202.5M | 197.5M | 167.8M | 183.0M | 173.0M | 128.6M | 118.9M |
| Research and development | 31.0M | 28.5M | 28.7M | 38.9M | 35.5M | 24.2M | 23.0M | 23.1M | 19.5M | 13.4M |
| Selling, general and administrative | 226.5M | 181.5M | 209.0M | 157.4M | 169.8M | 141.1M | 143.0M | 140.6M | 101.2M | 91.5M |
| Operating income | 33.7M | 38.9M | 5.74M | 6.20M | 8.12M | 2.44M | 17.0M | 9.31M | 7.97M | 21.8M |
| Depreciation and amortization | 22.5M | 24.2M | 23.1M | 22.4M | 24.0M | 20.7M | 18.3M | 18.1M | 9.74M | 8.38M |
| EBITDA | 56.2M | 63.1M | 28.8M | 28.6M | 32.1M | 23.2M | 35.4M | 27.4M | 17.7M | 30.2M |
| Interest expense | 26.6M | 34.3M | 25.3M | 18.2M | 16.9M | 16.7M | 14.9M | 15.8M | 4.90M | 3.00M |
| Income before tax | 14.8M | -7.51M | -21.6M | -15.0M | -14.8M | -17.2M | 1.64M | -6.39M | 3.56M | 18.4M |
| Income tax | 5.01M | 5.84M | 9.10M | 4.21M | 7.00K | -492.0K | -76.0K | -3.55M | -143.0K | 7.63M |
| Net income | 9.77M | -13.4M | -30.7M | -19.2M | -14.8M | -16.7M | 1.72M | -2.84M | 3.70M | 10.8M |
| Earnings per share, basic | 0.22 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.08 | 0.11 | 0.33 |
| Earnings per share, diluted | 0.21 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.08 | 0.11 | 0.32 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 64.9M | 53.5M | 58.9M | 39.4M | 55.0M | 61.4M | 33.8M | 41.5M | 40.0M | 56.6M |
| Short-term investments | 546.0K | 528.0K | 747.0K | 776.0K | 699.0K | |||||
| Receivables | 89.8M | 79.5M | 71.8M | 61.8M | 53.0M | 46.0M | 52.9M | 47.1M | 47.5M | 27.8M |
| Inventory | 92.4M | 79.8M | 82.0M | 74.5M | 77.0M | 73.0M | 53.1M | 45.5M | 46.7M | 26.3M |
| Current assets | 358.1M | 290.1M | 280.7M | 247.3M | 247.7M | 234.6M | 187.4M | 179.2M | 179.3M | 147.2M |
| Property, plant and equipment | 65.0M | 36.4M | 38.4M | 38.7M | 37.5M | 33.1M | 32.1M | 31.0M | 33.6M | 18.5M |
| Goodwill | 254.1M | 241.0M | 247.3M | 243.6M | 250.0M | 260.1M | 186.7M | 188.8M | 188.3M | 78.3M |
| Total assets | 884.8M | 789.1M | 792.4M | 762.8M | 793.1M | 789.4M | 605.7M | 571.1M | 589.7M | 316.1M |
| Accounts payable | 16.0M | 18.0M | 13.3M | 12.0M | 10.4M | 9.62M | 9.80M | 7.55M | 9.77M | 5.74M |
| Current liabilities | 101.6M | 66.8M | 57.9M | 49.7M | 45.0M | 60.5M | 45.2M | 34.5M | 42.9M | 30.1M |
| Long-term debt | 215.1M | 314.2M | 305.5M | 306.5M | 307.5M | 290.5M | 214.6M | 215.7M | 218.2M | 67.0M |
| Total debt | 215.1M | 314.3M | 307.0M | 308.1M | 309.1M | 291.7M | 215.7M | 216.9M | 219.0M | 71.6M |
| Total liabilities | 436.6M | 512.9M | 510.6M | 478.5M | 492.3M | 460.7M | 320.0M | 296.0M | 312.6M | 107.2M |
| Shareholders' equity | 448.2M | 276.2M | 281.8M | 284.3M | 300.7M | 328.7M | 285.7M | 275.1M | 277.1M | 209.0M |
| Shares outstanding | 48.8M | 48.8M | 47.9M | 41.8M | 42.0M | 41.2M | 40.6M | 40.1M | 39.0M | 39.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 39.9M | 22.2M | 18.8M | -5.15M | -2.58M | 12.4M | 15.8M | 9.88M | 10.8M | 19.7M |
| Capital spending | -39.0M | -11.2M | -9.75M | -10.7M | -13.1M | -7.33M | -8.07M | -5.79M | -6.63M | -6.20M |
| Free cash flow | 839.0K | 11.0M | 9.07M | -15.9M | -15.7M | 5.04M | 7.75M | 4.09M | 4.17M | 13.5M |
| Cash from investing | -42.0M | -28.2M | -502.0K | -10.7M | 5.66M | -73.1M | -23.9M | -6.71M | -171.0M | -78.9M |
| Cash from financing | 11.3M | 2.20M | 865.0K | -1.64M | -12.2M | 93.6M | -1.49M | -2.56M | 143.2M | 73.4M |
| Dividends paid | -3.76M | -2.43M | -4.76M | |||||||
| Share buybacks | 0 | 0 | -559.0K | -1.79M | -1.91M | -2.00M | -2.74M | -2.10M | -1.61M | -697.0K |
| Change in cash | 11.4M | -5.48M | 19.6M | -15.7M | -6.95M | 27.7M | -7.94M | 1.48M | -16.6M | 13.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| SD · Specialized disclosure | May 21, 2026 | ESG report | SEC |
| 4/A · Change in ownership, amended | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| 8-K · Current report | May 15, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 1, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 18, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| 5 · Annual statement of ownership | Jan 28, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Jan 28, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 29, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 15, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 8-K · Current report | May 28, 2025 | Financing | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 19, 2025 | ESG report | SEC |
| 8-K · Current report | May 16, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 14, 2025 | Financing | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 9, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 11, 2025 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Artivion, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 48,789,772
- Fully diluted
- 48,789,772
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 48,789,772 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 48,789,772 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lance Berry Other companies: Treace Medical Concepts, Inc. (Board Member · Since at least Oct 1, 2022); AEON Biopharma, Inc. (Director · Feb 8, 2021 – Feb 8, 2021 · Past); Vapotherm Inc (Director · Jan 29, 2020 – Sep 20, 2024 · Past); Wright Medical Group N.V (EVP, Chief Fin & Op Officer · Oct 1, 2015 – Nov 11, 2020 · Past) | Executive Vice President, Chief Operating Officer, and Chief Financial Officer · Since at least Dec 6, 2023 |
| Philip A Theodore Other companies: Medizone International Inc (Executive Vice President · Nov 1, 2017 – Jan 3, 2018 · Past); Zep Inc (VP & General Counsel · Jul 19, 2010 – Oct 1, 2014 · Past); Harland John H Co (SVP, General Counsel · Sep 5, 2006 – May 1, 2007 · Past); Serologicals Corp (Vice President · Jul 14, 2006 – Jul 14, 2006 · Past) | VP, General Counsel · Sep 4, 2007 – Sep 4, 2007 · Past |
| Harvey Morgan Other companies: Family Dollar Stores Inc (Director · Nov 5, 2007 – Jul 6, 2015 · Past); Cybex International Inc (Director · Jan 9, 2006 – Feb 7, 2013 · Past) | Director · May 1, 2008 – Aug 30, 2021 · Past |
| Jon W Salveson Other companies: Nuwellis, Inc. (Director · Mar 13, 2013 – May 19, 2023 · Past); Piper Sandler Companies (Global Head of Invest. Banking · Aug 11, 2006 – Feb 16, 2010 · Past) | Director · Since at least May 16, 2012 |
| James Benson Other companies: Nuo Therapeutics Inc (Director · Jan 12, 2006 – Mar 19, 2013 · Past) | Director · May 5, 2006 – Oct 2, 2017 · Past |
| James P Mackin Other companies: Wright Medical Group N.V (Director · Jun 29, 2018 – Nov 11, 2020 · Past) | President & CEO · Since at least Sep 2, 2014 |
| Jason Asper Other companies: Wright Medical Group N.V (SVP, Chief Digital Officer · Aug 14, 2017 – Nov 11, 2020 · Past) | Senior Vice President and Chief Strategy and Digital Officer · Since at least Nov 4, 2026 |
| Jeff Burbank Other companies: NxStage Medical Inc (Chief Executive Officer, Director · Jun 8, 2006 – Feb 21, 2019 · Past) | Lead Director · Since at least Dec 18, 2017 |
| Jeffrey W Burris Other companies: Supernus Pharmaceuticals, Inc. (Chief Legal Officer · Since at least Jan 1, 2026) | Vice President & Gen. Counsel · Feb 16, 2010 – Aug 15, 2014 · Past |
| Thomas F. Ackerman Other companies: Charles River Laboratories International, Inc. (Corporate Executive VP & CFO · Feb 17, 2006 – May 15, 2015 · Past) | Executive Vice President and Chief Financial Officer · Since at least May 5, 2006 |
All 50 people
| Person | Seat |
|---|---|
| Albert E Heacox | Sr. VP Research and Devl · Feb 21, 2006 – Dec 31, 2011 · Past |
| Amy D. Horton | Vice President, Chief Accounting Officer · Since at least Jun 5, 2019 |
| Andrew M. Green | Senior Vice President, Regulatory and Quality · Since at least Mar 8, 2021 |
| Anthony Semedo | Director · Since at least Oct 1, 2021 |
| Brian Johnston | Executive Vice President · Since at least Oct 28, 2026 |
| Bruce G Anderson | VP, US Sales &Global Marketing · Dec 10, 2012 – Mar 7, 2015 · Past |
| Carlos Soto | Vice President, Global Manufacturing · Since at least Nov 4, 2026 |
| C Elkins Ronald | Director · May 5, 2006 – Sep 5, 2018 · Past |
| Daniel J. Bevevino | Director · Since at least May 5, 2006 |
| David Ashley Lee | Executive VP, COO & CFO · Feb 21, 2006 – Mar 1, 2023 · Past |
| David C Gale | VP, Research & Development · Jan 1, 2012 – Nov 16, 2017 · Past |
| David Fronk | VP, Regulatory Affairs · Dec 31, 2005 – Mar 7, 2015 · Past |
| David P Lang | VP, Int'l Sales & Marketing · Dec 10, 2012 – Feb 26, 2015 · Past |
| Dennis B Maier | SVP, Operations · May 25, 2018 – Jun 6, 2023 · Past |
| Elizabeth A. Hoff | Consultant and Founder · Since at least Oct 1, 2022 |
| Florian Tyrs | VP, Global Operations · Jun 23, 2023 – Feb 27, 2024 · Past |
| Franz Peter Barthold | VP, Research & Development · Jul 1, 2020 – Nov 8, 2022 · Past |
| Gerald B Seery | Sr. VP, Sales and Marketing · Feb 21, 2006 – Nov 30, 2012 · Past |
| James Bullock | Director · Since at least Nov 8, 2016 |
| Jean F. Holloway | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary · Since at least Apr 1, 2015 |
| Jim Bullock | Since at least May 20, 2026 |
| John E. Davis | Chief Commercial Officer · Since at least Sep 10, 2015 |
| John M Cook | Director · May 5, 2006 – Jun 9, 2009 · Past |
| Jon W. Salveson | Vice Chairman, Investment Banking · Since at least May 20, 2026 |
| J. Patrick Mackin | Chairman, President and Chief Executive Officer · Since at least Nov 4, 2026 |
| Marna P. Borgstrom | Chief Executive Officer · Since at least Jun 19, 2018 |
| Marshall S Stanton | SVP, Clinical & MD Affair · Since at least Mar 8, 2021 |
| Matthew A. Getz | Vice President, Chief Human Resources Officer · Since at least Jul 31, 2019 |
| Michael S Simpson | SVP, Regulatory Affairs and QA · Dec 3, 2018 – Mar 5, 2021 · Past |
| Robert C. Thomson | Vice President, Research and Development · Since at least Jun 8, 2023 |
| Rochelle L. Maney | Vice President, Global Quality · Since at least Mar 8, 2021 |
| Ronald D McCall | Director · Jan 3, 2006 – Aug 25, 2021 · Past |
| Scott B Capps | VP, Clinical Research · Oct 29, 2007 – Mar 12, 2021 · Past |
| Sherry M Saurini | VP, Quality · Feb 19, 2016 – Mar 14, 2019 · Past |
| Sidney B Ashmore | Vice President of Marketing · Jan 18, 2006 – Jan 18, 2006 · Past |
| Simona Zannetti | Senior Vice President of Clinical Research and Chief Medical Officer · Since at least Nov 4, 2026 |
| Steven G Anderson | Former Executive Chairman · Nov 18, 2011 – Apr 9, 2015 · Past |
| Thomas J Bogenschuetz | VP, EMEA & General Manager · May 25, 2018 – May 5, 2020 · Past |
| Virginia C Lacy | Director · May 5, 2006 – Apr 24, 2007 · Past |
| William Robert Matthews | Senior VP, Operations, Quality · Sep 13, 2016 – Mar 5, 2018 · Past |
Log in to ask 6ix AI your own questions about Artivion, Inc.